Expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.

This resolution would designate September 2026 as "Sickle Cell Disease Awareness Month" and encourage public programs to raise awareness of the sickle cell trait, prevention, care, and treatments. Sickle cell disease affects about 100,000 people in the U.S., causes severe pain and organ damage, and results in roughly 1,800–2,000 births each year. More than 2 million Americans carry the sickle cell trait, including about 1 in 13 Black Americans. The resolution notes FDA approvals of two cell-based gene therapies in 2023 and an expanded Casgevy approval in July 2026, and it calls for more research and public outreach to improve early detection, preventive care, and patient services.